Armephaco JSC

Armephaco JSC Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Armephaco JSC (AMP.VN) as of Oct 31, 2026 is -8.18. In the previous year, Net Debt to Free Cash Flow Ratio was 24.87 — a change of -132.90% (lower).

Net Debt/FCF

-8.18

YoY

-132.90%

Last updated:

Net Debt to Free Cash Flow Ratio of Armephaco JSC is 2024 -8.18 . Net Debt to Free Cash Flow Ratio of Armephaco JSC was 2023 24.87 . It decreases by -132.90% lower compared to the previous year.

The Armephaco JSC Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
-99.78 VND
Jan 1, 2018
-28.14 VND
Jan 1, 2019
162.92 VND
Jan 1, 2020
-20.92 VND
Jan 1, 2021
5.17 VND
Jan 1, 2022
33.58 VND
Jan 1, 2023
24.87 VND
Jan 1, 2024
-8.18 VND
The Armephaco JSC Net Debt/FCF history
YEARNet Debt/FCFYoY
-8.18-132.90%
24.87-25.92%
33.58+549.92%
5.17-124.70%
-20.92-112.84%
162.92-678.99%
-28.14-71.80%
-99.78+4,133.32%
-2.36-87.85%
-19.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Armephaco JSC Stock analysis

What does Armephaco JSC do? Armephaco JSC manufactures pharmaceutical and medical equipment products, focusing on glucose meters, sphygmomanometers, beds, medical exam tables, stools, and syringe destroyers. The company distributes medical devices and equipment through its manufacturing and distribution channels, targeting healthcare providers and hospitals. It also produces and trades diversified medicines, including antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs, serving the broader healthcare market. The firm generates revenue from the sale of medical devices and equipment, as well as from pharmaceutical products. Healthcare providers and hospitals purchase the medical devices and equipment, while the diversified medicines are sold to pharmacies and healthcare institutions. Armephaco JSC's product portfolio includes glucose meters, sphygmomanometers, beds, medical exam tables, stools, syringe destroyers, antibiotics, vitamins, pain relievers, antipyretics, gastrointestinal, and anti-allergic drugs. Armephaco JSC's business model centers on the production and distribution of medical devices and pharmaceuticals. The company's primary customers are healthcare providers, hospitals, pharmacies, and healthcare institutions. The revenue streams are derived from the direct sale of medical equipment and pharmaceutical products to these segments, with no mention of additional services or partnerships. Armephaco JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Armephaco JSC stock

Net Debt to Free Cash Flow Ratio of Armephaco JSC is -8.18 in 2024.

Net Debt to Free Cash Flow Ratio of Armephaco JSC changed from 24.87 to -8.18, representing a -132.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Armephaco JSC since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Armephaco JSC with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Armephaco JSC

All Key Metrics — Armephaco JSC